Analysis of vitamin D receptor gene polymorphisms in vitiligo

Dermatology

Volumn 224, Issue 4, 2012, Pages 361-368

  Aydngz, Ikbal Esen ^a   Bingül, Ilknur ^b   Doǧru Abbasoǧlu, Semra ^b   Vural, Pervin ^b   Uysal, Müjdat ^b  

^a ACIBADEM UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Calcitriol receptors; Genetic polymorphism; Haplotypes; Vitamin D; Vitiligo

Indexed keywords

DNA; VITAMIN D RECEPTOR;

ADULT; AGED; APAI GENE; ARTICLE; BSMI GENE; CDX2 GENE; CONTROLLED STUDY; DNA EXTRACTION; DNA ISOLATION; FEMALE; FOKI GENE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RISK FACTOR; TAQI GENE; VITAMIN D RECEPTOR GENE; VITILIGO;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; RISK FACTORS; VITILIGO; YOUNG ADULT;

EID: 84864869305     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000339340     Document Type: Article

References (53)

1. Le Poole IC, Wankowics-Kalinska A, van den Wijngaard RM, Nickoloff BJ, Das PK: Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004; 9: 68-72.
2. Maresca V, RoccellAm, Roccella F, Camera E, Del Porto G, Passi S, Grammatico P, Picar-do M: Increased sensitivity to peroxidative agents as a possible pathogenic factor of me-lanocyte damage in vitiligo. J Invest Dermatol 1997; 109:310-313.
3. Zhang XJ, Chen JJ, Liu JB: The genetic concept of vitiligo. J Dermatol Sci 2005; 39:137-146.
4. Parsad D, Kamwar AJ: Topical vitamin D analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009; 22:487-488.
5. Rodriguez-Martin M, Garcia Bustinduy M, Saez Rodriguez M, Noda Cabrera A: Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult non-segmental vitiligo. Br J Dermatol 2009; 160: 409-414.
6. Arca E, Tastan HB, Erbil AH, Sezer E, Koç E, Kurumlu Z: Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006; 33:338-343.
7. Goldinger SM, Dummer R, Schmid P, Burg G, Seifert B, Läuchli S: Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007; 21:504-508.
8. Birlea SA, Costin GE, Norris DA: Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitili-go depigmentation. Curr Drug Targets 2008; 9: 345-359.
9. Adorini L: Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol 2005; 233: 115-124.
10. Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA: Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J Steroid Biochem Mol Biol 2004; 89-90: 187-193.
11. Martin RJ, McKnight AJ, Patterson CC, Sad-lier DM, Maxwell AP; Warren 3/UK Go-KinD Study Group: A rare haplotype of the vitamin D receptor gene is protective against diabetic nephropathy. Nephrol Dial Transplant 2010; 25:497-503.
12. Kim HS, Newcomb PA, Ulrich CM, Keener CL, Bigler J, Farin FM, Bostick RM, Potter JD: Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers Prev 2001; 10:869-874.
13. Flügge J, Krusekopf S, Goldammer M, Oss-wald E, Terhalle W, Malzahn U, Roots I: Vitamin D receptor haplotypes protect against development of colorectal cancer. Eur J Clin Pharmacol 2007; 63: 997-1005.
14. Önen IH, Ekmekçi A, Eroglu M, Konaç E, Yesil S, Biri H: Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp Biol Med 2008; 233: 1608-1614.
15. Bai Y, Yu Y, Yu B, et al: Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet 2009; 10: 125.
16. Jenab M, McKay J, Bueno-de-Mesquita HB, et al: Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations. Cancer Epidemiol Biomarkers Prev 2009; 18: 2485-2491.
17. Birlea S, BirleAm, Cimponeru D, Apostol P, Cosgarea R, Gavriala L, Tigan S, Costin G, Gas P: Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm Venereol 2006; 86: 209-214.
18. Faraco JE, Morrison NA, Baker A, Shine J, Frossard PM: ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res 1989; 17:2150.
19. Morrison NA, Qi JC, Tokita A, et al: Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367:284-287.
20. Morrison NA, Yeoman R, Kelly PJ, Eisman JA: Contribution of transacting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci USA 1992; 89:6665-6669.
21. Barrett JC, Fry B, Maller J, Daly MJ: Haplo-view: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
22. Günes S, Bilen CY, Kara N, Asçi R, Bagci H, Yilmaz AF: Vitamin D receptor gene polymorphisms in patients with urolithiasis. Urol Res 2006; 34: 47-52.
23. Dayangaç-Erden D, Karaduman A, Erdem-Yurter H: Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 2007; 299:487-491.
24. Yoldemir T, Yavuz DG, Anik G, Verimli N, Erenus M: Vitamin D receptor gene polymorphisms in a group of postmenopausal Turkish women: association with bone mineral density. Climacteric 2011; 14: 392-397.
25. Stathopoulou MG, Dedoussis GVZ, Trovas G, Theodoraki EV, Katsalira A, Dontas IA, Hammond N, Deloukas P, Lyritis GP: The role of vitamin D receptor gene polymorphisms in the bone mineral density of Greek postmenopausal women with low calcium intake. J Nutr Biochem 2011; 22: 752-757.
26. Macdonald HM, McGuigan FE, Stewart A, Black AJ, Fraser WD, Ralston S, Reid DM: Large-scale population-based study shows no evidence of association between common polymorphism of the VDR gene and BMD in British women. J Bone Miner Res 2006; 21: 151-162.
27. Fang Y, van Meurs JB, d'Alesio A, Jhamai M, Zhao H, Rivadeneira F, Hofman A, van Leu-wen JP, Jehan F, Pols HA, Uitterlinden AG: Promoter and 3'-untranslated-region haplo-types in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam study. Am J Hum Genet 2005; 77:807-823.
28. Grundberg E, Lau EM, Pastinen T, Kind-mark A, Nilsson O, Ljungren O, Mellstrom D, Orwoll E, Redlund-Johnell I, Holmberg A, Gurd S, Leung PC, Kwork T, Ohlsson C, Mallmin H, Brandstrom H: Vitamin D receptor 3'-haplot y pes are unequa l ly expressed in primary human bone cells and associated with increased fracture risk: the MrOS study in Sweden and Hong Kong. J Bone Miner Res 2007; 22: 832-840.
29. Çiçek MS, Liu X, Schomacher FR, Casey G, Witte JS: Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15:2549-2552.
30. Crofts LA, Hancock MS, Morrison NA, et al: Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA 1998; 95:10529-10534.
31. Ismail S, Erfan M, Abd El-Salam M, Kamal S, Ibrahim S, Nasr H: Vitamin D receptor gene polymorphism and growth pattern in Egyptian rachitic children. Life Sci J 2011; 8: 120-131.
32. Valdivielso JM, Fernandez E: Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371:1-12.
33. Arai H, Miyamoto KI, YoshidAm, Yamamo-to H, Taketani Y, Morita K, KubotAm, Yo-shida S, IkedAm, Watabe F, Kanemasa Y, Takeda E: The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 2001; 16:1256-1264.
34. Silverberg JI, Silverberg AI, Malka E, Silverberg NB: A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010; 62: 937-941.
35. Cicarma E, Mørk C, Porojnicu AC, Juze-niene A, Tam TT, Dahlback A, Johan M: Influence of narrowband UVB phototherapy on vitamin D and folate status. Exp Dermatol 2010; 19:e67-e72.
36. Gamil H, Attwa E, Ghonemy S: Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo. Clin Exp Dermatol 2010; 35: 919-921.
37. Matsuzaki J, Tsuji T, Zhang Y, Wakita D, Imazeki I, Sakai T, Ikeda H, Nishimura T: 1alpha,25-dihydroxyvitamin D3 downmod-ulates the functional differentiation of Th1 cytokine-conditioned bone marrow-derived dendritic cells beneficial for cytotoxic T lym-phocy te generation. Cancer Sci 2006; 97: 139-147.
38. Wankowicz-Kalinska A, van den Wijngaard RM, Tigges BJ, Westerhof W, Ogg GS, Ce-rundolo V, Storkus WJ, Das PK: Immunopo-larization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003; 83: 683-695.
39. Moretti S, Fabbri P, Baroni G, Berti S, Bani D, Berti E, Nassini R, Lotti T, Massi D: Kera-tinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histo-pathol 2009; 24:849-857.
40. Yee YK, Chintalacharuvu SR, Lu J, Nagpal S: Vitamin D receptor modulators for inflammation and cancer. Mini Med Rev Chem 2005; 5:761-778.
41. Yamanaka K I, Kaked AM, Kitagawa H, Tsuda K, Akeda T, Kurokawa I, Gabazza EC, Kupper TS, Mizutani H: 1,24-dihydroxyvitamin D (tacalcitol) prevents skin T-cell infiltration. Br J Dermatol 2010; 162:1206-1215.
42. Adorini L: Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2002; 2: 1017-1028.
43. Kingo K, Reimann E, Karelson M, Ratsep R, Raud K, Vasar E, Silm H, Koks S: Association analysis of genes of the IL19 cluster and their receptors in vitiligo patients. Dermatology 2010; 221:261-266.
44. Watabe H, Soma Y, Kawa Y, Ito M, Ooka S, Ohsumi K, Baba T, Kawakami T, Hosaka E, Kimura S, Mizoguchi M: Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 2002; 119: 583-589.
45. Katayama I, AshidAm, Maeda A, Eishi K, Murota H, Bae SJ: Open trial of topical tacal-citol 1 alpha 24(OH)2D3 and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol 2003; 13: 372-376.
46. TachibanAm: MITF: a stream flowing for pigment cells. Pigment Cell Res 2000; 13: 230-240.
47. Schallreuter KU, Gibbons NC, Zothner C, Abou Elloof MM, Wood JM: Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: more evidence for oxidative stress in vitiligo. Biochem Bio-phys Res Commun 2007; 360:70-75.
48. Carsberg CJ, Warenius HM, Friedmann PS: Ultraviolet radiation-induced melanogene-sis in human melanocytes. Effects of modulating protein kinase C. J Cell Sci 1994; 107: 2591-2597.
49. Wong G, Gupta R, Dixon KM, et al: 1,25-di-hydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Bio-chem Mol Biol 2004; 89-90: 567-570.
50. Hann SK, Norlund JJ: Vitiligo. Oxford, Blackwell Science, 2000, pp 3-6.
51. Namian AM, Shahbaz S, Salmanpoor R, Namazi MR, Dehghani F, Kamali-Sarvestani E: Association of inter feron-gAmma and tumor necrosis factor alpha polymorphisms with susceptibility to vitiligo in Iranian patients. Arch Dermatol Res 2009; 301: 21-25.
52. De Haes P, Garmyn M, Verstuyf A, De Clerc P, Vandewalle M, Degreef H, Vantieghem K, Bouillon R, Segaert S: 1,25-dihydroxyvita-min D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol 2005; 78:141-148.
53. Sauer B, Ruwisch L, Kleuser B: Antiapoptot-ic action of 1alpha,25-dihydroxyvitamin D3 in primary human melanocytes. Melanoma Res 2003; 13: 339-347.